Clinical trial
A phase 2a, double-blind, placebo-controlled study of TCN-032 (human monoclonal antibody directed against the M2 protein of Influenza A Virus) in subjects challenged with H3N2 Influenza A Virus
The primary objective is to evaluate the effect of TCN-032 compared to placebo in the development of influenza symptoms Grade 2 or higher, or pyrexia, from Day 1 to Day 7, after viral challenge.
| Category | Value |
|---|---|
| Study start date | 2012-04-25 |